SE8304393L - Naproxen- och naproxennatriumtabletter av controlled release-typ - Google Patents

Naproxen- och naproxennatriumtabletter av controlled release-typ

Info

Publication number
SE8304393L
SE8304393L SE8304393A SE8304393A SE8304393L SE 8304393 L SE8304393 L SE 8304393L SE 8304393 A SE8304393 A SE 8304393A SE 8304393 A SE8304393 A SE 8304393A SE 8304393 L SE8304393 L SE 8304393L
Authority
SE
Sweden
Prior art keywords
naproxen
controlled release
weight percent
release type
sodium tablets
Prior art date
Application number
SE8304393A
Other languages
Unknown language ( )
English (en)
Other versions
SE454565B (sv
SE8304393D0 (sv
Inventor
C H Hsiao
J S Kent
Original Assignee
Syntex Pharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24004892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8304393(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Pharma Int filed Critical Syntex Pharma Int
Publication of SE8304393D0 publication Critical patent/SE8304393D0/sv
Publication of SE8304393L publication Critical patent/SE8304393L/sv
Publication of SE454565B publication Critical patent/SE454565B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
SE8304393A 1983-06-14 1983-08-12 Tablett av controlled release-typ innehallande naproxen eller naproxennatrium SE454565B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/504,112 US4571333A (en) 1983-06-14 1983-06-14 Controlled release naproxen and naproxen sodium tablets

Publications (3)

Publication Number Publication Date
SE8304393D0 SE8304393D0 (sv) 1983-08-12
SE8304393L true SE8304393L (sv) 1984-12-15
SE454565B SE454565B (sv) 1988-05-16

Family

ID=24004892

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8304393A SE454565B (sv) 1983-06-14 1983-08-12 Tablett av controlled release-typ innehallande naproxen eller naproxennatrium

Country Status (24)

Country Link
US (2) US4571333A (sv)
AT (1) AT389225B (sv)
AU (1) AU552080B2 (sv)
BE (1) BE899885A (sv)
CA (1) CA1204671A (sv)
CH (1) CH643455A5 (sv)
DE (1) DE3329265A1 (sv)
DK (1) DK162814C (sv)
FI (1) FI83037C (sv)
FR (1) FR2547498B1 (sv)
GB (1) GB2141338B (sv)
HK (1) HK95590A (sv)
IE (1) IE55585B1 (sv)
IL (1) IL69371A0 (sv)
IT (1) IT1200967B (sv)
LU (1) LU84962A1 (sv)
MY (1) MY100439A (sv)
NL (1) NL191669C (sv)
NO (1) NO167001C (sv)
NZ (1) NZ204708A (sv)
PH (1) PH17827A (sv)
SE (1) SE454565B (sv)
SG (1) SG80990G (sv)
ZA (1) ZA835591B (sv)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061897A (en) * 1976-01-23 1977-12-06 Audrae Thykeson Heating pad
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US5225201A (en) * 1991-08-23 1993-07-06 Minnesota Mining And Manufacturing Company Salsalate tablet
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
DE69301742T2 (de) * 1992-02-17 1996-08-14 Siegfried Ag Pharma Darreichungsformen mit verlaengerter Wirkstoffreigabe
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
CA2144077C (en) * 1992-09-18 2005-05-24 Kazuhiro Sako Hydrogel-type sustained-release preparation
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US6080888A (en) * 1997-01-08 2000-06-27 Albemarle Corporation Preparation of olefinic compounds and carboxylic derivatives thereof
US5792886A (en) * 1997-01-08 1998-08-11 Albemarle Corporation Production of racemic 2-(6-methoxy-2-naphthyl) propionic acid of precursors thereof
US6096920A (en) * 1997-01-08 2000-08-01 Albemarle Corporation Preparation of carboxylic compounds and their derivatives
US5859292A (en) * 1997-12-11 1999-01-12 Albemarle Corporation Preparation of high purity sodium (S)-2(6-methoxy-2-naphthyl)propionate
US5874614A (en) * 1997-12-11 1999-02-23 Albemarle Corporation Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate
US7235258B1 (en) * 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
US7999118B2 (en) 2000-01-18 2011-08-16 Albemarle Corporation Process for producing N-halogenated hydantoins
US7579018B2 (en) * 2000-01-18 2009-08-25 Albemarle Corporation Microbiological control in aqueous systems
US6495698B1 (en) 2000-01-18 2002-12-17 Albemarle Corporation Binder-free compacted forms of 1,3-dihalo-5,5-dimethylhydantoins
US6809205B1 (en) 2000-01-18 2004-10-26 Albemarle Corporation Process for producing N-halogenated organic compounds
US6448410B1 (en) 2000-01-18 2002-09-10 Albemarle Corporation Production of compacted biocidal agent from particulate biocidal agent without using a binder
US6508954B1 (en) 2000-01-18 2003-01-21 Albemarle Corporation 1,3-dibromo-5,5-dimethylhydantoin of enhanced properties
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
US20050049420A1 (en) * 2000-01-18 2005-03-03 Elnagar Hassan Y. Process for producing N-halogenated organic compounds
US6565868B1 (en) 2000-01-18 2003-05-20 Albemarle Corporation Methods for microbiological control in aqueous systems
US7371397B2 (en) * 2000-01-18 2008-05-13 Albemarle Corporation Methods for microbiological control in aqueous systems
US6638959B2 (en) 2000-01-18 2003-10-28 Albemarle Corporation Microbiological control in aqueous systems
WO2003011033A1 (en) * 2001-06-28 2003-02-13 Solution Biosciences, Inc. Microbiological control in animal processing
US6986910B2 (en) * 2001-06-28 2006-01-17 Albemarle Corporation Microbiological control in poultry processing
US6908636B2 (en) * 2001-06-28 2005-06-21 Albermarle Corporation Microbiological control in poultry processing
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
BR0212259A (pt) * 2001-08-29 2004-10-19 Ranbaxy Lab Ltd Formulação de liberação controlada de claritromicina ou tinidazol
US20090178587A9 (en) * 2001-10-09 2009-07-16 Nalepa Christopher J Control of biofilms in industrial water systems
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
US20040010024A1 (en) * 2002-07-10 2004-01-15 Howarth Jonathan N. Particulate blends and compacted products formed therefrom, and the preparation thereof
US6965035B1 (en) 2002-07-25 2005-11-15 Albemarle Corp Compacted forms of halogenated hydantoins
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040228918A1 (en) * 2003-01-02 2004-11-18 Chih-Ming Chen Granule modulating hydrogel system
CA2513893A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20040265445A1 (en) * 2003-06-24 2004-12-30 Liimatta Eric W. Microbiocidal control in the processing of poultry
US20040265446A1 (en) * 2003-06-24 2004-12-30 Mcnaughton James L. Microbiocidal control in the processing of poultry
US7901276B2 (en) * 2003-06-24 2011-03-08 Albemarle Corporation Microbiocidal control in the processing of meat-producing four-legged animals
WO2005011682A1 (ja) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. 経口徐放性錠剤
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
AU2004326202B2 (en) * 2004-12-23 2011-11-10 Albemarle Corporation Microbiocidal control in the processing of meat-producing four-legged animals
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
BRPI0620851B1 (pt) * 2005-12-01 2016-08-23 Albemarle Corp método para controle microbiano no processo de produção de carne de animais quadrúpedes
AU2008261957A1 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
BR112013000190A2 (pt) 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
US9415048B2 (en) * 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120244218A1 (en) 2011-03-25 2012-09-27 Durkee Shane E Calcium supplement
CN106880614A (zh) * 2017-04-06 2017-06-23 地奥集团成都药业股份有限公司 一种萘普生缓释片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2146564A5 (sv) * 1971-07-19 1973-03-02 Peugeot & Renault
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets

Also Published As

Publication number Publication date
FR2547498B1 (fr) 1986-06-13
AU1801183A (en) 1984-12-20
IL69371A0 (en) 1983-11-30
PH17827A (en) 1985-01-07
CA1204671A (en) 1986-05-20
SE454565B (sv) 1988-05-16
CH643455A5 (de) 1984-06-15
IT1200967B (it) 1989-01-27
NO167001B (no) 1991-06-17
DK162814B (da) 1991-12-16
NL191669B (nl) 1995-10-02
LU84962A1 (de) 1983-12-28
US4571333A (en) 1986-02-18
DK553683A (da) 1984-12-15
AU552080B2 (en) 1986-05-22
DK162814C (da) 1992-05-04
NO167001C (no) 1991-09-25
NO842362L (no) 1984-12-17
FR2547498A1 (fr) 1984-12-21
DK553683D0 (da) 1983-12-01
AT389225B (de) 1989-11-10
NL191669C (nl) 1996-02-05
GB8321757D0 (en) 1983-09-14
FI83037B (fi) 1991-02-15
DE3329265A1 (de) 1984-12-20
FI842400A0 (fi) 1984-06-13
GB2141338A (en) 1984-12-19
HK95590A (en) 1990-11-23
IT8367870A0 (it) 1983-08-12
ATA191084A (de) 1989-04-15
FI83037C (sv) 1991-05-27
ZA835591B (en) 1985-03-27
SG80990G (en) 1990-11-23
SE8304393D0 (sv) 1983-08-12
DE3329265C2 (sv) 1991-04-11
MY100439A (en) 1990-09-29
FI842400A (fi) 1984-12-15
IE55585B1 (en) 1990-11-07
IE831799L (en) 1984-12-14
BE899885A (fr) 1984-12-12
US4803079A (en) 1989-02-07
NZ204708A (en) 1984-12-14
GB2141338B (en) 1988-06-02
NL8302842A (nl) 1985-01-02

Similar Documents

Publication Publication Date Title
SE8304393L (sv) Naproxen- och naproxennatriumtabletter av controlled release-typ
Lanza A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects
AU635881B2 (en) Oral anticoagulant/platelet inhibitor low dose formulation
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
UY23804A1 (es) Procedimiento de preparacion de medicamentos en forma de comprimidos con liberacion retardada de sustancia activa.
ES2090368T3 (es) Composiciones farmaceuticas que contienen glucosaminoglicanos absorbibles por via oral.
DK0797435T3 (da) Matrice til kontrolleret frigivelse af lægemidler
ES8402155A1 (es) Un metodo para producir formas posologicas unitarias solidas que al administrarse siguen una pauta de liberacion regular y prolongada.
NO20065390L (no) Farmasoytisk preparat i fast enhetsdoseringsform
ATE198835T1 (de) Knochenwachstumsfördernde zusammensetzung
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
RU2000131897A (ru) Пероральная дозировочная композиция пролонгированного действия
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
RU93004785A (ru) Твердые капсулы окфосфата цитарабина
CA2123332A1 (en) Controlled Release Formulation of Diltiazem Hydrochloride
GB9420748D0 (en) 1,5 benzodiazepine derivatives
NO964775L (no) Fast farmasöytisk adenosinholdig preparat
RU96113328A (ru) Способ торможения фиброзообразования
RU97119670A (ru) Способ профилактики иксодовых клещевых боррелиозов

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8304393-5

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8304393-5

Format of ref document f/p: F